Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT01526681

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

RANGER: University Hospital, Vienna, Austria

Loading trial locations.

About this study

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft.

Addendum 1 (MATCH) establishes a comparative arm to collect data on nerve injuries repaired with nerve autografts and nerve tube conduits at select RANGER® participating sites.

Addendum 2 (Sensation-NOW) establishes a focused arm to collect data on autologous breast reconstructive procedures where neurotization was completed. Post-mastectomy autologous breast reconstruction procedures without neurotization will serve as an internal control group to allow for comparisons.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Primary Study Criteria (RANGER Avance):

Inclusion criteria

  • Males and Females who have undergone nerve repair using the Avance® Nerve Graft for the repair of a nerve injury
  • Returned for at least one post-operative follow-up visit

Exclusion criteria

  • Subject who in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up.

Addendum 1 (MATCH) Criteria:

Inclusion criteria

  • Have nerve transection injuries to the upper extremity;
  • Have undergone tension free end to end nerve coaptation on both the proximal and distal portion of the nerve gap with nerve autograft or nerve entubulation with nerve tube conduit at a participating ANG-CP-005 registry site after 2004 and;
  • Have completed sufficient follow-up assessments at a regeneration rate of 2mm/day to determine the outcomes of the repair or is willing to comply with site specific post-operative care procedures and assessments to determine the outcome of the repair.

Exclusion criteria

  • Direct nerve repairs;
  • Nerve gaps greater than 70mm;
  • Subjects who, in the opinion of the investigator, were non-compliant to the investigator's post-operative treatment or rehabilitation instructions;
  • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.

Addendum 2 (Sensation-NOW) Criteria:

Inclusion criteria

  • Female ≥ 18 years old
  • Undergo post mastectomy autologous breast reconstruction with one type of autologous flap (no stacked reconstructions or use of implant with autologous flap)
  • Neurotization must be completed using a donor nerve from the flap and a recipient nerve from the chest
  • Complete Sensory Assessment Testing with Semmes Weinstein Monofilaments (SWMF) and the following Breast-Q Questionnaires 60 - 120 days post-reconstruction:
  • Breast-Q Physical Well Being of the Chest
  • Breast-Q Satisfaction with Breast
  • Breast-Q Physical Well Being of the Abdomen
  • Breast-Q Abnormal Breast Sensations
  • Breast-Q Impact of Breast Sensation on Quality of Life
  • Breast-Q Return of Breast Sensation
  • Able to provide informed consent and are willing to comply with post-operative care procedures and assessments

Exclusion criteria

  • Surgical history of secondary revision surgery for partial or total flap loss
  • Bilateral reconstruction with non-uniform treatment (i.e. 1 reconstructed breast is non-neurotized, 1 reconstructed breast is neurotized)
  • Currently prescribed medication known to impact nerve regeneration or to cause peripheral neuropathy
  • Currently undergoing IV chemotherapy or radiation
  • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study or is unlikely to comply with follow-up schedule

Additional Eligibility criteria to Modules

Module 1: Native Skin Reconstructions with and without neurotization.

  • Buried flap reconstructions from nipple sparing mastectomy or skin sparing mastectomy OR a breast reconstruction from a skin sparing mastectomy with exposed flap skin in the peri-areolar region.
  • Sensory assessments must be completed on ≥ 8 Zones of Native Skin.
  • Center zone measurement may be on either Native Skin or Flap Skin.
  • All Inner and Outer zone measurements must be on Native Skin.
  • De-identified photo of the breast reconstruction with 9 zones identified.

Treatment and study plan

Processed Human Nerve Graft

Other

Implantation of appropriate length of processed human nerve graft at the time of surgery

Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.

Other

Historical control from established literature

Autogenous Nerve Graft

Other

Nerve gap reconstructions with autogenous nerve graft within the upper extremity

Nerve Tube Conduit

Device

Nerve gap reconstructions with nerve tube conduit within the upper extremity

Autologous Breast Reconstruction with Neurotization

Procedure

Autologous Breast Reconstruction without Neurotization

Procedure

Primary outcomes

  1. Avance Nerve Graft: Incidence of Avance Nerve Graft Related Adverse Events

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed through the course of their recovery based on Physician's standard of care practice or until lost to follow-up.

  2. RANGER and MATCH: Sensory Function as measured by Medical Research Council Classification (MRCC) for sensory recovery

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for a change in sensory function, if applicable, of the reconstructed peripheral nerve through the course of their follow-up using Physician's standard of care sensory assessments or until lost to follow-up.

  3. RANGER and MATCH: Motor Function as measured by Medical Research Council Classification (MRCC) for motor recovery

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for a change in motor function, if applicable, to the reconstructed peripheral nerve through the course of their follow-up using Physician's standard of care motor assessments or until lost to follow-up.

  4. Sensation-NOW- Breast Neurotization: Sensory Function Post Autologous Breast Reconstruction

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for change in sensation through the course of their recovery using Physician's standard of care assessments or until lost to follow-up. Standard of care sensory assessment includes evaluation using Semmes Weinstein Monofilament kit measured in g/mm2.

  5. Sensation-NOW- Breast Neurotization: Quality of Life Measurement Post Autologous Breast Reconstruction

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for change in quality of life as measured by Breast Q through the course of their recovery or until lost to follow-up using Physician's standard of care assessments. Standard of care assessments may include evaluation of quality of life via other scales or may be qualitatively documented.

  6. Incidence of conduit, autograft, or procedure related adverse events

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed through the course of their recovery based on Physician's standard of care practice or until lost to follow-up.

Secondary outcomes

  1. Pain Level

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for a change in pain level as measured by VAS, when available, through the course of their recovery using Physician's standard of care assessments for pain or until lost to follow-up.

  2. RANGER and/or MATCH: Quality of Life Following Reconstruction of Peripheral Nerve

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for change in quality of life as measured by Disabilities of the Arm Shoulder and Hand Questionnaire (DASH), if available, through the course of their recovery or until lost to follow-up using Physician's standard of care assessments. Standard of care assessments may include evaluation of quality of life via other scales or may be qualitatively documented.

  3. Cost of Care

    Time frame: Through study completion or until lost to follow-up, approximately 3 years

    Participants will be followed for cost of care, as converted to USD, from the surgical nerve procedure through the course of their recovery or until lost to follow-up using available data in the medical record from Physician's standard of care.

Sponsors and collaborators

Lead sponsor

Axogen Corporation

Industry

Registry information

Official study title

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Acronym: RANGER®

Important dates

Study start
2008
Primary completion
2028
Study completion
2028
First posted
Feb 6, 2012
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.